HC Wainwright & Co. Reiterates Buy Rating on Nurix Therapeutics, Inc. (NRIX)

Market Context

Nurix Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $24.42 with a market capitalization of $1.5B. The stock has gained 135.9% over the past 52 weeks.

Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Nurix Therapeutics, Inc.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Nurix Therapeutics, Inc.

Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Oct 16, 2026	HC Wainwright & Co.	Buy	N/A
Oct 13, 2026	RBC Capital	Outperform	N/A
Oct 13, 2026	Truist Securities	Buy	N/A
Oct 13, 2026	Oppenheimer	Outperform	N/A
Oct 13, 2026	Baird	Outperform	N/A

Related Tools: Analyst Ratings Dashboard | View NRIX Stock Page